• Categories:Company news
• Author:
• Origin:
• Time of issue:2022-03-21 16:57
• Views:0

(Summary description)For a long time, dyslipidemia is an important cause of cardiovascular and cerebrovascular diseases, and cardiovascular and cerebrovascular diseases have become the number one killer that threatens people's lives and health. According to the data, there are about 290 million people with cardiovascular disease in my country, and about 3 million people die of cardiovascular disease every year, accounting for more than 40% of the deaths of residents, ranking first. A few days ago, the quantum lipid-lowering instrument developed by Changchun Xianying Medical Technology Co., Ltd. was put into clinical application in the Chinese People's Liberation Army General Hospital (Beijing 301 Hospital). Emerging technologies for the treatment of dyslipidemia bring painless, risk-free and safer new treatments to the majority of patients.

Focus on disease prevention and control, to achieve preventable and curable dyslipidemia

Changchun Xianying Medical Technology Co., Ltd., as a high-tech start-up enterprise focusing on the research and development and production of high-quality medical equipment, with a modern enterprise system and cultural atmosphere, has developed a quantum lipid-lowering instrument for the prevention and treatment of dyslipidemia. In the prevention and treatment of diseases such as diseases, it has also developed a series of products such as "diabetes treatment machine" and "Alzheimer's disease treatment equipment" with original innovative technology.

It is reported that the quantum lipid-lowering instrument currently being put into clinical application in hospitals is a large-scale medical device developed by Xianying Medical. Sun Dechun told reporters, "Those who can go to large hospitals for diagnosis and treatment are, after all, a small number of critically ill patients. My goal is to make as many patients as possible. Those in need can easily use the quantum lipid-lowering instrument, get rid of hyperlipidemia and its induced cardiovascular and cerebrovascular diseases, return to a healthy life, and truly realize the preventable and curable dyslipidemia. On the basis of the lipid-lowering instrument, a small quantum lipid-lowering instrument has also been developed to achieve the goal of allowing the quantum lipid-lowering instrument to enter thousands of households and help patients with dyslipidemia return to a healthy life.

　　　　

 


　　

Focus on research and development, to be a leading manufacturer of high-tech medical equipment research and development

Changchun Xianying Medical Technology Co., Ltd. is an enterprise specializing in the medical device industry. It is committed to being a leading high-tech medical device R&D and manufacturing manufacturer, and is committed to becoming one of the innovative leading companies in the medical device field. Since its establishment in 2007, Xianying Medical has been adhering to the concept of "focusing on health and caring for life", adhering to the enterprise spirit of "innovation, dedication, diligence and efficiency", and regards the maintenance of life and health as its responsibility.

For a long time, Xianying Medical has devoted itself to the research and development of medical devices for dyslipidemia, arteriosclerosis, diabetes and other diseases using biophysical theory, and has a strong R&D team. The Key Laboratory of Academician Ren Luquan, the academician, has cooperated to jointly research and develop products in the field of big health. In 2013, Xianying Medical cooperated with the Suzhou Institute of Biomedical Engineering Technology of the Chinese Academy of Sciences to establish a quantum biology engineering technology center. Based on quantum biology technology, through the study of biomolecular structure, electromagnetic properties, energy conversion and chemical reactions, from molecular At the electronic level, we can study and explain life phenomena and study life processes, and develop a series of medical products and related solutions for the field of metabolic syndrome and autoimmune diseases.

　　　　

 

　　It is understood that tracking the development of modern medicine and establishing a modern high-tech group integrating R&D, production and sales are the company's current strategic goals.